Business
Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
– Commenced patient dosing in lorundrostat pivotal clinical program, for the treatment of patients with uncontrolled or resistant hypertension in April 2023 –
About this update from Mineralys Therapeutics, Inc.
[{"type":"text","content":"– Commenced patient dosing in lorundrostat pivotal clinical program, for the treatment of patients with uncontrolled or resistant hypertension in April 2023 – – Plan to initiate the second pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled or resistant hypertension in the second half of 2023 – – Plan to initiate a Phase 2 trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled or resistant hypertension in a chronic kidney disease (CKD) population – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced financial results for the quarter ending March 31, 2023, and provided a corporate update. “This year is off to a strong start as we continued to build momentum developing lorundrostat for the targeted treatment of hypertension. Most recently we started dosing patients in our confirmatory pivotal Advance-HTN trial evaluating the safety and efficacy of lorundrostat for the treatment of uncontrolled or resistant hypertension. We expect this trial to readout topline data in the first half of 2024,” stated Jon Congleton, Chief Executive Officer of Mineralys Therapeutics. “In addition, we plan to initiate a second lorundrostat pivotal trial named Launch-HTN in the second half of 2023, which is expected to readout topline data in mid-2025. We believe our current cash, cash equivalents and investments will fund our planned clinical studies and support our operations through mid-2025.” Recent Corporate and Clinical Highlights Initiated pivotal Advance-HTN trial – In April 2023, the Company initiated patient dosing in the Advance-HTN Phase 2 trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), when used as an add-on therapy to standardized background treatment of two or three antihypertensive medications in up to approximately 300 adult subjects. The topline data from this trial is expected in the first half of 2024.Target-HTN trial presented at ACC.23/WCC – In March 2023, the Company presented positive data from the Target-HTN Phase 2 tri...